Olympus jumps through final anti-trust hoops for Gyrus acquisition
This article was originally published in Clinica
Executive Summary
Olympus' proposed £935m ($1.8bn) acquisition of UK firm Gyrus has received the go-ahead from anti-trust authorities in Germany and Austria. In addition to the US approval gained in December 2007, the transaction has cleared all the required anti-trust hurdles. Gyrus, which specialises in minimally-invasive surgery, agreed to be acquired by Japanese group Olympus in November for £6.30 per share (see Clinica No 1283, p 1).
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.